To understand the parameters required for designing potent and specific antisense C-5 propynylpyrimidine-2′-deoxyphosphorothioate-modified oligonucleotides (C-5 propyne ONs), we have utilized a HeLa line that stably expresses luciferase under tight control of a tetracycline-responsive promoter. Using this sensitive and regulatable cell-based system we have identified five distinct antisense ONs targeting luciferase and have investigated the role that ON length, target mismatches, compound stability and intracellular RNA levels play in affecting antisense potency. We demonstrate that C-5 propyne ONs as short as 11 bases retained 66% of the potency demonstrated by the parent 15 base compound, that a one base internal mismatch between the antisense ON and the luciferase target reduced the potency of the antisense ON by 43% and two or more mismatches completely inactivated the antisense ON and that C-5 propyne ONs have a biologically active half-life in tissue culture of 35 h. In addition, by regulating the intracellular levels of the luciferase mRNA over 20-fold, we show that the potency of C-5 propyne ONs is unaffected by changes in the expression level of the target RNA. These data suggest that low and high copy messages can be targeted with equivalent potency using C-5 propyne ONs.
INTRODUCTION
Traditional pharmaceutical drug candidates are identified by screening large chemical libraries. A promising compound is characterized by its ability to bind to a target protein and alter its normal biological function. In contrast, antisense-based therapeutic compounds, oligonucleotides (ONs), can be rationally designed to inhibit protein expression from any gene for which a partial sequence is known.
Recent technological advances, (i) the incorporation of nuclease-resistant backbone modifications into ONs, (ii) the discovery that C-5 propynylpyrimidine-modified phosphorothioate oligonucleotides have enhanced affinity for their RNA target and (iii) the development of cationic lipids to efficiently deliver ONs to cells, have overcome many of the barriers limiting the use of antisense in biological systems (1) (2) (3) (4) (5) (6) (7) (8) . It now appears that antisense-based drugs will be viable human therapeutics. In fact, clinical trials using antisense ONs containing phosphorothioate backbones have been initiated for several human diseases (4, 9) .
Despite the rapid progress in developing antisense ONs as human therapeutics, there is concern that many of the biological and clinical effects observed are not due to an antisense mechanism alone (10) (11) (12) (13) . Recently, Kreig et al. showed that oligonucleotides containing CpG (cytosine-phosphate-guanine) can mimic bacterial DNA and trigger a potent immune response (14) . Such non-antisense effects, while clinically benefical, undermine the promise of antisense agents as sequence-specific therapeutic agents. Clearly, the ultimate success of antisense therapeutics as rationally designed drugs relies on demonstrating that the clinical benefits can be attributed to an antisense mechanism of action.
In an effort to understand the parameters that influence the potency and specificity of C-5 propyne antisense ONs, we have used the HeLa X1/5 cell line, which stably expresses luciferase under control of a tetracycline-responsive promoter, to study the effects that ON length, non-complementary RNA/ON binding, compound stability and intracellular RNA levels have on C-5 propyne-modified antisense-mediated inhibition of luciferase expression.
MATERIALS AND METHODS

Cell culture
The HeLa X1/5 cell line stably expresses luciferase and has been described in detail (15) . Briefly, HeLa X1/5 cells contain a tetracycline-controlled transactivator that was produced by fusing the tet repressor with the activating domain of virion protein 16 (VP16) of herpes simplex virus. The tet-VP16 transactivator is constitutively expressed in the cells. This transactivator stimulates transcription of a stably integrated luciferase gene by binding to tetracycline operator sequences found upstream of the luciferase gene. In the presence of tetracycline (1 µg/ml), the tet repressor binds tetracycline and blocks binding to the tet operator sequences. Thus, the presence of tetracycline in the HeLa X1/5 growth medium inhibits luciferase gene expression. In the absence of tetracycline, HeLa X1/5 cells maximally express luciferase. Cells were grown in Dulbecco's modified Eagle's medium (DMEM) + 10% fetal bovine serum (FBS).
ON synthesis
ONs were synthesized using the H-phosphonate method using standard procedures (16) (17) (18) . The location of the ONs is based on the sequence of Photinus pyralis luciferase (accession no. M15077; 19).
Preparation of the GS2888 cytofectin/oligonucleotide complex
To prepare the cytofectin/ON complexes for transfection in one well of a 6-well tissue culture plate, the ON was first diluted into 100 µl pre-warmed Opti-MEM (Gibco BRL) in polystyrene plastic. Similarly, the cytofectin was diluted in another container (5) . The pre-diluted ON and cytofectin mixtures were next combined (again in polystyrene plastic) and within 15 min 800 µl of the appropriate pre-warmed (37_C) medium (with serum) was added. Medium was next removed from the cells and replaced with the medium containing the ON/cytofectin complex.
Antisense assays
The HeLa X1/5 cells were seeded onto 6-well tissue culture plates at a density of 5 × 10 5 cells/well in DMEM + 10% FBS. The following day the cells were transfected for 4 h using either antisense ONs or mismatch sequence ONs (see Table 1 , underlining indicates mismatch positions). At defined time points, cell extracts were made using Reporter Lysis buffer (Promega Corp., Madison, WI). Luciferase enzyme activity was quantified using a single photon liquid scintillation counter (LS6500, Beckman, Palo Alto, CA) as described (20) . Percent luciferase activity is expressed as the ratio of the relative light units detected from the luciferase enzyme assays for the ON-treated samples relative to the control cells treated with GS2888 cytofectin alone.
RNA analysis
RNA was prepared from the treated cells using Trizol reagent (Gibco BRL) according to the manufacturer's instructions. Total RNA (10 µg/lane) was electrophoresed through a 1.2% agarose-6% formaldehyde gel, transferred to Hybond-N (Amersham) and UV-crosslinked to the membrane using a UV-Stratalinker (Stratagene). The blot was hybridized as described (21) and probed overnight at 42_C with a random primer (Promega)-generated luciferase DNA probe. A glyceraldehyde 3-phosphate dehydrogenase (GAPDH) probe (Ambion Inc.) was used as an internal control. Following hybridization, the blot was washed three times with 2× SSC, 0.1% SDS at 65_C and exposed to X-ray film. Luciferase mRNA levels were determined using a radioanalytic imager and normalized to GAPDH RNA levels (Ambis, San Diego, CA).
RESULTS
Identification of luciferase antisense ONs
We screened five different 15 base C-5 propyne antisense ONs directed against luciferase mRNA and found that all the ONs demonstrated sequence-specific antisense inhibition. The RNA location, size, C-5 propyne content and sequence of the ONs are shown in Table 1 . The inhibitory concentration (IC 50 ), where 50% of the luciferase enzyme activity is inhibited following antisense ON treatment, was determined. The IC 50 for the antisense ONs Lucif-1, Lucif-2, Lucif-3 and Lucif-4 was between 1 and 2 nM when delivered to the HeLa X1/5 cells using GS2888 cytofectin. In the absence of GS2888 cytofectin, no antisense activity was observed for any of the ONs. The IC 50 for antisense ON Lucif-5 was 5 nM.
Dose-response curves for two of the antisense ONs, Lucif-2 and Lucif-5, and their corresponding mismatch ONs are shown A range of ON concentrations (1, 3, 9 and 27 nM) were delivered to the HeLa X1/5 cells using 2.5 µg/ml GS2888 cytofectin. Extracts were prepared 24 h later and assayed for luciferase activity. Percent luciferase activity is the relative light units detected from the luciferase enzyme assay in ON-treated samples relative to control cells treated with GS2888 cytofectin alone. The experiments were done in triplicate and the values for each of the points varied by <5%.
in Figure 1 . The range of the doses was from 1 to a maximum of 27 nM of antisense or mismatch ONs. A dramatic decrease in luciferase activity was observed at all concentrations of the antisense ONs. As indicated above, the IC 50 of Lucif-2 is between 1 and 2 nM and that of Lucif-5 is 5 nM. Essentially complete inhibition of luciferase activity was demonstrated at 27 nM Lucif-2. The IC 50 of Lucif-2.MM, an 8 base mismatch of Lucif-2, and Lucif-5.MM, a 4 base mismatch, was estimated to be 180 nM (extrapolated IC 50 values; Fig. 1A; 5) . Only a modest decrease in luciferase activity was observed with between 1 and 9 nM Lucif-2.MM. Both mismatch ONs are 20-to 30-fold less active at inhibiting luciferase enzyme activity than the antisense ONs, consistent with previous microinjection data using C-5 propynemodified ONs (1, 3) . For the remainder of the results, data will be shown for Lucif-2, although similar results were obtained for the other luciferase antisense ONs.
Antisense activity and ON length
To investigate the relationship between ON length and C-5 propyne antisense activity, we tested two 13mer, 11mer and 9mer antisense ONs made by shortening the Lucif-2 15mer by 2 base intervals from either the 5′-or 3′-end of the ON (see Table 1 for Figure 2 . Relationship between antisense potency and ON length. Different 13mer, 11mer and 9mer C-5 propyne-modified antisense ONs based on the Lucif-2 sequence were individually delivered to HeLa X1/5 at 25 nM each using GS2888 (2.5 µg/ml) cytofectin and assayed for luciferase enzyme activity 6 h following transfection. Results from ONs shortened from the 5′-end and the 3′-end of Lucif-2 are shown in the left and right panels respectively. To determine how rapidly luciferase activity could be diminished in 6 h, HeLa X 1/5 cells were treated with tetracycline (1 µg/ml) under the same conditions as the antisense ON transfection and assayed for luciferase activity. Sequence and propyne content of the antisense ONs are shown in Table 1 . Percent luciferase activity was determined as indicated in Materials and Methods. The experiments were done in duplicate and the values for each of the points varied by <5%. the sequences). Previously, we have shown that shorter ONs persist in the nucleus of the cell for less time than longer (15mer) ONs (22) , therefore, cellular extracts were prepared 6 h rather than 24 h following ON delivery, so that we could observe the full antisense effect of the shorter ONs.
As seen in Figure 2 , Lucif-2 used at 25 nM demonstrated a significant antisense-specific decrease (59%) in luciferase activity after only 6 h. Shortening the Lucif-2 antisense ON to a 13mer by removing 2 bases from either the 5′-or 3′-end had only a modest effect on the potency of the ONs. Lucif-2.5′.13mer and Lucif-2.3′.13mer inhibited luciferase enzyme activity by 54 and 48% respectively (Fig. 2) . Further shortening of Lucif-2 to an 11mer by removing 4 bases at either the 5′-or 3′-end still resulted in antisense-specific inhibition of luciferase activity, with Lucif-2.5′.11mer and Lucif-2.3′.11mer inhibiting luciferase activity by 39 and 33% respectively. Remarkably, when Lucif-2 was trimmed to 9 bases, Lucif-2.5′.9mer and Lucif-2.3′.9mer still inhibited luciferase activity by 10 and 17% respectively. Lucif-2.MM, the mismatch ON, had no effect on luciferase activity under these conditions (Fig. 2) .
The effect of mismatches on antisense ON potency
The potency of an antisense ON is dependent on precise binding to its target. Mismatches between the antisense ON and its target reduce the effectiveness of the antisense ON to inhibit gene Figure 3 . The effect of mismatches on antisense potency. Four mismatch ONs were tested at 10 nM each using GS2888 cytofectin at 2.5 µg/ml for antisense-specific inhibition of luciferase enzyme activity. Protein extracts were made 24 h later and assayed for luciferase activity. Both one base mismatch ONs (Lucif-2.MM1A and Lucif-2.MM1B) inhibited luciferase enzyme activity by 48%. Antisense ONs containing two or more mismatches failed to demonstrate any antisense activity (Lucif-2.MM2 and Lucif-2.MM). The ONs sequences are shown in Table 1 . The experiments were done in triplicate and the values for each of the points varied by <5%.
expression (1) . To determine how mismatches affect the potency of C-5 propyne-modified antisense ONs we synthesized 1, 2 and 8 base mismatches of Lucif-2 and tested their ability to inhibit luciferase activity.
Two different 1 base mismatch ONs were synthesized and tested for antisense activity at 10 nM ON concentration. Lucif-2.MM1A substituted the guanosine at position 7 with a C-5 propyne uridine. Lucif-2.MM1B substituted the guanosine at position 7 with a C-5 propyne cytosine (see Table 1 ). The mismatch ONs retained ∼60% of the activity of Lucif-2, despite the 1 base mismatch (Fig. 3) . Mismatch ONs containing 2 base changes at positions 7 and 8 failed to demonstrate any antisense activity (Fig. 3) . The 8 base mismatch (Lucif-2.MM) also failed to inhibit luciferase activity.
Duration of antisense activity in tissue culture
To determine the potency of C-5 propyne-modified antisense ONs observed over time in tissue culture, we delivered Lucif-2 (30 nM) or Lucif-2.MM, the mismatch ON, into HeLa X1/5 cells using GS2888 cytofectin and monitored luciferase enzyme activity at various times following transfection (Fig. 4) . Antisense-specific inhibition of luciferase activity was seen at 6 h following transfection, the earliest point tested, and persisted for at least 48 h. Maximum inhibition of luciferase activity was observed between 18 and 24 h following transfection and Lucif-2 inhibited luciferase activity by at least 50% for 35 h after transfection (Fig. 4) . were delivered to HeLa X1/5 cells using GS2888 cytofectin (2.5 µg/ml). Extracts were prepared at various times following transfection and assayed for luciferase activity. Percent luciferase activity was determined as indicated in Materials and Methods. The experiment was repeated in duplicate and similar results were obtained.
Antisense potency is independent of intracellular RNA levels
HeLa X1/5 cells stably express luciferase under tight control of a tetracycline-responsive promoter. By varying the tetracycline concentration in the tissue culture medium (0-1 µg/ml), the luciferase mRNA levels can be regulated over a wide range (15) . HeLa X1/5 cells were treated with varying concentrations of tetracycline (0-1 µg/ml) for 24 h and RNA was isolated for Northern blot analysis (Fig. 5A) . Luciferase RNA was maximally expressed in the absence of tetracycline and at a tetracycline concentration of 0.0001 µg/ml (Fig. 5A, lanes 1 and 2) . A 10-fold increase in tetracycline (0.001 µg/ml) resulted in a 2-fold decrease in luciferase mRNA levels (compare lanes 1 and 2 with lane 3, Fig. 5 ). Increasing tetracycline concentrations to 0.01 µg ml reduced luciferase mRNA levels 20-fold (Fig. 5A,  lane 4) . At 0.1-1.0 µg/ml tetracycline, luciferase mRNA expression was completely inhibited (Fig. 5A, lanes 5 and 6) .
To examine the relationship between intracellular mRNA levels and antisense potency, HeLa X1/5 cells that had been treated with either 0.001 or 0.01 µg/ml tetracycline for 24 h were then transfected with Lucif-2 or Lucif-2.MM (1-27 nM ON) using GS2888 cytofectin. In HeLa X1/5 cells (no tetracycline treatment) maximally expressing luciferase mRNA the IC 50 of Lucif-2 was previously demonstrated to be between 1 and 2 nM (Fig. 1) . Surprisingly, the IC 50 of Lucif-2 antisense ON in HeLa X1/5 cells treated with 0.001 µg/ml tetracycline, which expressed 2-fold less luciferase RNA, was also between 1 and 2 nM (Fig.  5B) . Moreover, HeLa X1/5 cells treated with 0.01 µg/ml tetracycline, which reduced luciferase RNA levels 20-fold as compared with untreated HeLa X1/5 cells (Fig. 5A) , demonstrated an IC 50 of between 1 and 2 nM Lucif-2 (Fig. 5B) . These data indicate that the potency of the Lucif-2 antisense ON is independent of luciferase mRNA levels over a 20-fold range of RNA concentration. Futhermore, these data suggest that poorly expressed as well as highly expressed mRNA transcripts can be potently targeted by C-5 propyne-modified antisense ONs. 5) . GAPDH provides an internal control for loading and transfer of the RNA samples. (B) Dose-response characteristics of inhibition of luciferase enzyme activity in HeLa X1/5 cells treated with tetracycline at 0.0001 and 0.01 µg/ml for 24 h. Lucif-2 antisense ON and Lucif-2.MM were then delivered to cells using GS2888 (2.5 µg/ml) and extracts were made 24 h later and assayed for luciferase enzyme activity. Each of the above experiments were repeated in duplicate and similar results were obtained.
DISCUSSION
Using microinjection, we have previously shown that the biological potency of C-5 propyne antisense ONs is dependent on two critical parameters: ON length and precise binding of the antisense ON to its target (1, 3) . In the present study, we have extended these results and demonstrated (i) that antisense-specific inhibition is dependent on ON length, but that C-5 propyne-modified ONs as short as 11 bases demonstrate significant antisense-specific activity, (ii) that antisense inhibition can be demonstrated 6 h after delivering antisense ONs to cells, (iii) that antisense ONs retain at least 50% of their biological activity for 35 h in tissue culture and (iv) that the potency of C-5 propyne-modified antisense ONs is independent of the intracellular level of the target RNA.
The potency of C-5 propyne antisense ONs decreased with decreasing length, although 11mer antisense ONs retain 66% of the potency demonstrated by the parent 15mer. These results are similar to our previous results, in which we demonstrated by microinjection that a C-5 propyne-modified 11mer targeting SV-40 large T antigen (TAg) retained 10% of the potency of the 15mer (1). The differences in potency between the luciferase-specific 11mers and the TAg 11mer is not due to the number of C-5 propyne-modified bases, since the TAg 11mer is modified on 10 of 11 bases, whereas the luciferase 11mers contain only 8 or 6 C-5 propyne-modified bases. However, the antisense activity of these shorter ONs is dependent on the C-5 propyne modification. Previous studies using non-propyne phosphorothioate antisense ONs have found that ONs shorter than 15 bases fail to show any antisense activity (23) . In contrast, two C-5 propyne-modified luciferase antisense 9mer ONs were still potent enough to partially inhibit luciferase activity (Fig. 2) . The biological potencies of short ONs is in part determined by the availability of the target binding site to accommodate the antisense ON (24) . Some target binding sites may be readily accessible for binding, while other binding sites may be inaccessible due to the double-stranded nature of the RNA at that site. To date, identifying high affinity binding sites for short antisense ONs has been completely empirical.
Although the 9mer luciferase ONs only demonstrate weak inhibition of luciferase activity, these ONs provide a lead to develop additional ON base and backbone modifications to augment the affinity and, hence, potency of shorter antisense ONs. Clearly, the development of sequence-specific, potent, short ONs is essential in creating second generation antisense therapeutics for many reasons. First, toxicity associated with phosphorothioates could be reduced, since toxic effects of antisense phosphorothioate ONs closely correlates with ON length (25, 26) . Second, shorter ONs may be able to enter cells much more efficiently than longer ONs and, thus, demonstrate antisense inhibition at lower ON concentrations. Third, the cost of manufacturing antisense ONs would be dramatically reduced. Despite these advantages, there is a concern that non-targeted RNAs containing the luciferase 9mer binding site would also be inhibited. Clearly, many transcripts will contain the complementary 9mer binding site. However, as noted above, the structure or accessibility of the targeted RNA greatly influences the binding and, thus, the specificity of shorter antisense ONs (27) .
One of the promises of antisense technology is that the ONs are sequence specific. As shown in Figure 3 , C-5 propyne-modified ONs are sequence selective. A 1 base mismatch between Lucif-2 and the luciferase RNA reduced the potency of the ON by 43% and two mismatches completely eliminated activity of the antisense ON. The Lucif-2 antisense ON appears to be more sensitive to mismatches than we have observed for other sequences. Previously, we have shown that a C-5 propyne 17mer complementary to TAg had an IC 50 of 0.25 µM when microinjected into cells along with a TAg-expressing plasmid and the 2 base mismatch was 10-fold less potent (IC 50 2.5 µM). The sensitivity of antisense ONs to mismatches, although difficult to predict, is dependent on several factors, including the chemical modifications of the ON, which affect the affinity of the ON for its target, the sequence context as well as the position of the mismatch and the ON length.
ONs containing phosphodiester backbones have intracellular half-lives of 15-30 min and are poor antisense inhibitors. In contrast, ONs containing phosphorothioate linkages persist in the nucleus for >24 h following microinjection (22) . As demonstrated in this report, a C-5 propyne-modified phosphorothioate not only persists in the nucleus, but is biologically active from 6 to at least 48 h after delivery with GS2888 cytofectin. Luciferase enzyme activity was inhibited by 50% for 35 h after transfection with the C-5 propyne luciferase antisense ON.
Phosphorothioate ONs have the unique property of not only being resistant to intracellular nucleases, but also being able to recruit and activate RNAse H cleavage of the RNA portion of the RNA/ON hybrid. Numerous backbone analogs have been chemically synthesized, incorporated into ONs and shown to be resistant to intracellular nucleases (28, 29) , however, none have also been shown to be RNAse H competent or demonstrated enhanced antisense potency comparable with phosphorothioate ONs.
A striking finding of this report is that the potency of the C-5 propyne-modified ON is unaffected by 20-fold changes in target RNA levels. These data suggest that low or high copy messages can be targeted with equivalent potency. Intuitively, it seems that one would want to target low copy messages to maximize the potency of the antisense ON (30) . However, we observe no change in the IC 50 with increasing RNA levels. One interpretation of our data is that there is a depot of C-5 propyne-modified ON in the nucleus of the cell. This depot of ON may be transiently interacting with single-stranded DNA binding proteins, with DNA repair proteins, histones or other proteins that interact with polyanionic molecules and reside in the nucleus of the cell. When the level of targeted message RNA is increased, the depot of antisense ONs is recruited to bind to its high affinity receptor (targeted RNA). Thus, the intracellular store or depot of antisense ON is able to quickly buffer the effects of increased intracellular RNA levels and no change in the IC 50 is seen. Alternatively, there may be a threshold amount of free ON that degrades RNA in a catalytic fashion through the use of RNAse H.
For the development of antisense ONs as therapeutic agents, these results are very interesting, because the data suggest that antisense ONs can be used to target highly expressed RNA. Until now it was not known how RNA levels would affect antisense activity. Thus, overexpressed genes, such as those found in cancers, can be effectively inhibited by C-5 propyne-modified antisense ONs.
